upon its cellular mechanisms, and this definition should evolve as we further our understanding of what causes sarcopenia. I personally hope that is the case. However, I also appreciate that for this to be successful in the clinic, the medical community needs biomarkers of sarcopenia that can be relatively easily obtained, and it is clear that a muscle biopsy does not qualify in that respect. The comments made by Dr. Emanuele Marzetti (2) on this Viewpoint, which point out new advances in some blood-borne biomarkers that are now emerging, are thus very much appreciated. These and other advances will surely move us forward in meeting our goal of understanding and treating sarcopenia.
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